Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1476-1484

  Soraya, Hamid ^a   Khorrami, Arash ^a   Garjani, Afagh ^a   Maleki Dizaji, Nasrin ^a   Garjani, Alireza ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Electrocardiography; Isoproterenol; Metfromin; Myocardial infarction

Indexed keywords

ISOPRENALINE; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ELECTROCARDIOGRAM; HEART EDEMA; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART TO BODY WEIGHT RATIO; HISTOPATHOLOGY; MALE; NONHUMAN; R WAVE; RAT; SHAM PROCEDURE; ST SEGMENT ELEVATION; TREATMENT DURATION; WISTAR RAT;

EID: 84870456897     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70945-3     Document Type: Article

References (31)

1. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism, 2004, 53, 159-164. (Pubitemid 38168886)
2. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA: Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res, 1989, 65, 657-670. (Pubitemid 19226442)
3. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ: Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes, 2008, 57, 696-705.
4. Chagoya de Sánchez V, Hernández-Muñoz R, López-Barrera F, Yañez L, Vidrio S, Suárez J, Cota-Garza MD et al.: Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can J Physiol Pharmacol, 1997, 75, 1300-1311.
5. Charlon V, Boucher F, Mouhieddine S, de Leiris J: Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary artery ligation. Diabetes Metab, 1988, 14, 591-595.
6. Chin JT, Troke JJ, Kimura N, Itoh S, Wang X, Palmer OP, Robbins RC, Fischbein MP: A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. Yale J Biol Med, 2011, 84, 423-432.
7. Davis TM, Fortun P, Mulder J, Davis WA, Bruce DG: Silent myocardial infarction and its prognosis in a community-based cohort of type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia, 2004, 47, 395-399. (Pubitemid 38491234)
8. Forechi L, Baldo MP, Meyerfreund D, Mill JG: Granulocyte colony-stimulating factor improves early remodeling in isoproterenol-induced cardiac injury in rats. Pharmacol Rep, 2012, 64, 643-649.
9. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H: Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia, 1994, 37, 826-832. (Pubitemid 24247854)
10. Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, Garjani A, Maleki-Dizaji N: Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol, 2011, 666, 135-141.
11. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A et al.: Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res, 2009, 104, 403-411.
12. Hardie DG: AMP-activated protein kinase - an energy sensor that regulates all aspects of cell function. Genes Dev, 2011, 125, 1895-1908.
13. Hardie DG: The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci, 2004, 117, 5479-5487.
14. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology, 1992, 131, 1165-1173.
15. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49, 2063-2069.
16. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med, 2002, 137, 25-33. (Pubitemid 34705373)
17. Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S, Veres G et al.: Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation, 2009, 120, 677-686.
18. Kravchuk E, Grineva E, Bairamov A, Galagudza M, Vlasov T: The effect of etformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II. Exp Diabetes Res, 2011, 2011, 907-496.
19. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD: High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem, 1995, 270, 17513-17520.
20. Legtenberg RJ, Houston RJ, Oeseburg B, Smits P: Metformin improves cardiac functional recovery after ischemia in rats. Horm Metab Res, 2002, 34, 182-185. (Pubitemid 34553530)
21. Lexis C PH, van der Horst IC: Metformin to reduce heart failure after myocardial infarction (GIPS-III). http://clinicaltrials.gov/ct2/show/ NCT01217307.
22. Łabuzek K, Liber S, Gabryel B, Okopień B:Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep, 2010, 62, 827-848.
23. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G et al.: Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol, 2000, 10, 1247-1255.
24. Owen MR, Doran E, Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J, 2000, 15, 348, 607-614. (Pubitemid 30410251)
25. Rona G: Catecholamine cardiotoxicity: J Mol Cell Cardiol, 1985, 17, 291-306.
26. Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Bøtker HE et al.: Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol, 2008, 103, 82-87. (Pubitemid 351874532)
27. Towler M, Hardie D: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res, 2007, 100, 328-341.
28. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-865.
29. Verma S, McNeill JH: Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol, 1994, 266, H714-H719. (Pubitemid 24104818)
30. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, de Boer RA: Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol, 2011, 301, H459-468.
31. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001, 108, 1167-1174. (Pubitemid 32995375)